Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease
暂无分享,去创建一个
Simon R. Cherry | Harley I. Kornblum | S. Cherry | H. Kornblum | T. Toyokuni | K. Tatsukawa | D. Araujo | Tatsushi Toyokuni | Dalia M. Araujo | Keith J. Tatsukawa
[1] Elsdon Storey,et al. Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.
[2] Garrett E. Alexander. Basal ganglia , 1998 .
[3] James F. Young,et al. MicroPET: a high resolution PET scanner for imaging small animals , 1996, IEEE Nuclear Science Symposium Conference Record.
[4] W. Low,et al. Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's Disease , 1997, Neuroscience Research.
[5] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.
[6] J. Joyce,et al. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: Localization to intrinsic neurons and not to neocortical afferents , 1987, Neuroscience.
[7] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Brotchi,et al. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. , 1994, Neurological research.
[9] S. Snyder,et al. 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. , 1978, European journal of pharmacology.
[10] D. Hilt,et al. ret receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways. , 1997, Neuroscience.
[11] S. W. Davies,et al. Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum , 1988, Neuroscience.
[12] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[13] N W Kowall,et al. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[14] S. Folstein,et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. , 1990, The Journal of neuropsychiatry and clinical neurosciences.
[15] J. Leysen,et al. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. , 1982, Molecular pharmacology.
[16] Joseph B. Martin,et al. Huntington's Disease and Neurotoxins , 1992, Annals of the New York Academy of Sciences.
[17] R. Albin,et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.
[18] Paul Kinahan,et al. Analytic 3D image reconstruction using all detected events , 1989 .
[19] Joseph B. Martin,et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.
[20] K Minematsu,et al. Positron Emission Tomography for Quantitative Determination of Glucose Metabolism in Normal and Ischemic Brains in Rats: An Insoluble Problem by the Harderian Glands , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] S. Sesack,et al. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[23] Claire-Anne Gutekunst,et al. Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.
[24] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[25] S. Cherry,et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] A. Parent,et al. The response of striatal neuropeptide Y and cholinergic neurons to excitatory amino acid agonists , 1988, Brain Research.
[27] D. Graham,et al. Specific alterations in local cerebral glucose utilization following striatal lesions , 1982, Brain Research.
[28] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[29] F. Hefti,et al. Cholinergic regulation of hippocampal brain-derived neurotrophic factor mRNA expression: Evidence from lesion and chronic cholinergic drug treatment studies , 1993, Neuroscience.
[30] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[31] A. Reiner,et al. Relative Survival of Striatal Projection Neurons and Interneurons after Intrastriatal Injection of Quinolinic Acid in Rats , 1994, Experimental Neurology.
[32] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[33] C. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.
[34] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[35] R. Derynck,et al. Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor , 1998, Journal of neuroscience research.
[36] D. Guilloteau,et al. Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone. , 1993, Life sciences.
[37] M. Levivier,et al. Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. , 1998, Neurological research.
[38] R. Schwarcz,et al. Intracerebral quinolinic acid injection in the rat: Effects on dopaminergic neurons , 1986, Brain Research.
[39] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[40] Makler Pt,et al. Bone scintigraphy: differentiating benign cortical irregularity of the distal femur from malignancy. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[42] Joseph B. Martin,et al. Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions , 1989, Synapse.
[43] D. Schoepp,et al. Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter , 1992, Neurochemistry International.
[44] F. Gage,et al. Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum , 1984, Nature.
[45] J. Penney,et al. Huntingtin localization in brains of normal and Huntington's disease patients , 1997, Annals of neurology.
[46] S. Snyder,et al. Drug and neurotransmitter receptors in the brain. , 1984, Science.
[47] Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade. , 1995 .
[48] G. Paxinos. The Rat nervous system , 1985 .
[49] D. Brooks,et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.
[50] C. Ross,et al. Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.
[51] C. Markham,et al. Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.
[52] S. Tatter,et al. Effects of striatal excitotoxicity on huntingtin-like immunoreactivity , 1995 .
[53] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[54] D. Eidelberg,et al. [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.
[55] D. Hilt,et al. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid , 1997, Neuroscience.
[56] E. Azmitia,et al. Rapid serotonergic fiber sprouting in response to ibotenic acid lesion in the striatum and hippocampus. , 1995, Brain research. Developmental brain research.
[57] D. Brooks,et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.
[58] J. Penney,et al. Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study , 1992, Neuroscience.
[59] Dennis P. Nelson,et al. Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum , 1997, Journal of neurochemistry.
[60] B. Rosen,et al. PET- and MRI-Based Assessment of Glucose Utilization, Dopamine Receptor Binding, and Hemodynamic Changes after Lesions to the Caudate-Putamen in Primates , 1994, Experimental Neurology.
[61] P. Sanberg,et al. Differential loss of neurochemical markers following quinolinic acid-induced lesions of rat striatum , 1991, Experimental Neurology.
[62] Osman Ratib,et al. Interactive user-friendly image analysis of cardiac PET images on a low cost desktop computer , 1991, [1991] Proceedings Computers in Cardiology.
[63] R. Hichwa,et al. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.
[64] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[65] T. Chase,et al. D-1 dopamine receptor changes after striatal quinolinic acid lesion. , 1987, European journal of pharmacology.
[66] D. Hilt,et al. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease , 1997, Neuroscience.
[67] Roger N. Gunn,et al. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.
[68] S. Folstein,et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.
[69] D. Riche,et al. A Primate Model of Huntington'S Disease: Functional Neural Transplantation and Ct-Guided Stereotactic Procedures , 1992, Cell transplantation.